Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interactions Between Azvudine and Rilpivirine
NCT07001488Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azvudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Genuine Biotech. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 56, Time to Maximum Plasma Concentration at Steady State at Day 56 and 1 more. Started Feb 2022; status: completed.
02
Drugs
azvudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07001488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001488.